Headline Expenditure Projections
- Pharmaceuticals: From EUR276mn (USD364mn) in 2013 to EUR291mn (USD390mn) in 2014; +5.6% in local currency terms and +7.2% in US dollar terms. The local currency growth forecast of 5.6% in 2014 is a modest increase after 2013's 5.3%, but the forecast continues on a long-term decline after 2014. The 2014 local currency forecast represents a marked decline from the growth of 9.2% in 2012 due to new market data and macroeconomic expectations.
- Healthcare: EUR1.12bn (USD1.48bn) in 2013 to EUR1.15bn (USD1.54bn) in 2014; +2.3% in local currency terms and +3.9% in US dollar terms .
Estonia scores 50.9 out of 100 in BMI's Pharmaceutical Risk/Reward Rating (RRR) tool, remaining in 10 th
position out of the 20 key markets covered in Central and Eastern Europe. Estonia's Industry Rewards score is still the weakest part of its pharmaceutical profile, at now 11.6 after 12.8 in Q214, significantly below the regional average of 19.0. That it scores as high as it does is mainly due to above-average scores in the urban/rural split and pensionable...
The Estonia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Estonia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Estonian pharmaceutical and healthcare industry.Key Benefits
CoverageBMI Industry View & Industry SWOT
- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Estonia to test other views - a key input for successful budgeting and strategic business planning in the Estonian pharmaceutical and healthcare market.
- Target business opportunities and risks in the Estonian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Estonia.
- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.Market Summary
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.Regulatory Regime
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)
Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)
OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.Company Profiles
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
Estonia will continue to present a relatively limited market for pharmaceuticals despite having a positive business environment. The reason for that is limited growth in pharmaceutical spending in Estonia as the Estonian government's policy of fiscal restraint continues. Fiscal tightening has lead to pressure on the Estonian Health Insurance Fund to rein in pharmaceutical expenditure through pricing limits, generic prescribing and reference pricing mechanisms on reimbursed drugs. Whether or not a fiscally conservative policy in healthcare spending can survive Estonia's ageing population and the subsequent growth in demand for medicine is highly dependent on broader macroeconomic trends. Nevertheless, there are also potential rewards in the market. Any growth in demand for medicine is highly dependent on unemployment levels and the raising of premiums by the HIF.